^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KLF4 overexpression

i
Other names: KLF4, EZF, GKLF, Kruppel-like factor 4 (gut)
Entrez ID:
Related biomarkers:
2ms
The mechanisms of tumor necrosis factor α in regulating Krüpple-like factor 4 expression in SK-BR-3 breast cancer cells. (PubMed, Asia Pac J Clin Oncol)
TNF-α promotes KLF4 expression, while TNF-α promotes apoptosis in SK-BR-3 cells, a process that may be due to elevated KLF4 protein expression.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
3ms
KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells. (PubMed, Front Immunol)
KLF14 also activated the JNK pathway to induce S-phase arrest and promote the expression of CDK2 and CCNA2. In summary, KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells.
Journal
|
CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • KLF14 (KLF Transcription Factor 14) • MAPK8 (Mitogen-activated protein kinase 8)
|
KLF4 overexpression • CCNA2 expression • CDK2 expression
5ms
Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia (ASH 2023)
Finally, we investigated whether pharmacological induction of KLF4 using APTO-253, a small-molecule inducer of KLF4, could control leukemia...Moreover, pharmacological induction of KLF4 demonstrated anti-leukemic activity in T-ALL cells. These findings propose a promising strategy for patients with T-ALL and 5' TAL1 SE.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MYB (MYB Proto-Oncogene, Transcription Factor) • KLF4 (Kruppel-like factor 4) • TAL1 (TAL BHLH Transcription Factor 1)
|
KLF4 overexpression
|
APTO-253
9ms
KLF4 targets RAB26 and decreases 5-FU resistance through inhibiting autophagy in colon cancer. (PubMed, Cancer Biol Ther)
Accumulating studies demonstrated that resistance of colon cancer (CC) to 5-fluorouracil (5-FU) contributes to adverse prognosis...Autophagy activator Rapamycin or sh-RAB26 treatment reversed the impact of KLF4 overexpression on 5-FU resistance...Rescue experiments revealed that KLF4 targeted RAB26 to inhibit CC cell autophagy, resulting in decreasing the resistance to 5-FU. KLF4 strengthened the sensitivity of CC cells to 5-FU by targeting RAB26 to restrain autophagy pathway.
Journal
|
KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
|
5-fluorouracil • sirolimus
10ms
Effect of Mir-4270 Inhibitor and Mimic on Viability and Stemness Gene Expression in Gastric Cancer Stem-Like Cells Derived from MKN-45 Cell Line. (PubMed, Iran Biomed J)
The cells were confirmed by differentiation assays using dexamethasone and insulin as adipogenesis-inducing agents and also Staurosporine as a neural-inducing agent...However, hsa-miR-4270 mimic had opposite effects on the cell viability and gene expression of the stem cell markers. Effect of hsa-miR-4270 inhibitor and mimic on the expression of the stem cell markers in GCSCs indicated that hsa-miR-4270 stimulates the stemness property of GCSCs, likely through stimulating the development of gastric stem cells.
Preclinical • Journal
|
CD44 (CD44 Molecule) • KLF4 (Kruppel-like factor 4) • SOX2 • NANOG (Nanog Homeobox)
|
KLF4 overexpression
|
dexamethasone
11ms
Circ_0020256 induces fibroblast activation to drive cholangiocarcinoma development via recruitment of EIF4A3 protein to stabilize KLF4 mRNA. (PubMed, Cell Death Discov)
We also found circ_0020256 accelerated CCA tumor growth in vivo. In conclusion, circ_0020256 promoted fibroblast activation to facilitate CCA progression via EIF4A3/KLF4 pathway, providing a potential intervention for CCA progression.
Journal
|
IL6 (Interleukin 6) • KLF4 (Kruppel-like factor 4) • TGFB1 (Transforming Growth Factor Beta 1) • EIF4A3 (Eukaryotic Translation Initiation Factor 4A3)
|
KLF4 overexpression
1year
Modulation of Spheroid Forming Capacity and TRAIL Sensitivity by KLF4 and Nanog in Gastric Cancer Cells. (PubMed, Curr Issues Mol Biol)
KLF4 is supposed to play a critical role in DR4/DR5 expression and responses to TRAIL and cisplatin, whereas Nanog is only implicated in the former events only. Direct regulation of death receptor expression and TRAIL response by KLF4 and Nanog have not been well documented previously, and the regulatory mechanism behind the process remains to be elucidated.
Journal
|
KLF4 (Kruppel-like factor 4) • SOX2 • NANOG (Nanog Homeobox) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
KLF4 overexpression • SOX2 expression
1year
KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2. (PubMed, J Exp Clin Cancer Res)
KLF14 acts as a tumor suppressor which inhibits the proliferation of HCC cells by modulating cellular iron metabolism via the repression of IRP2. We identified Fluphenazine, as an activator of KLF14, could be a potential compound for HCC therapy. Our findings therefore provide an innovative insight into the pathogenesis of HCC and a promising therapeutic target.
Journal
|
TFRC • SIRT1 (Sirtuin 1) • IREB2 (Iron Responsive Element Binding Protein 2)
|
KLF4 overexpression
|
fluphenazine
over1year
Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC. (PubMed, Biomedicines)
This work strongly suggests that an pEMT-like pathway is activated in recurrent and Cisplatin-resistant HNSCC. Finally, stable KLF4-overexpression might sensitize HNSCC tumor cells for Cisplatin treatment.
Journal
|
KLF4 (Kruppel-like factor 4) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
KLF4 overexpression
|
cisplatin
almost2years
KLF4 suppresses the proliferation and metastasis of NSCLC cells via inhibition of MSI2 and regulation of the JAK/STAT3 signaling pathway. (PubMed, Transl Oncol)
In conclusion, KLF4 significantly inhibited the proliferation, invasion and migration of NSCLC cells via inactivation of MSI2/JAK2/STAT3 signalling pathway. Thereby, our finding might shed new lights on exploring the new strategies against NSCLC.
Journal
|
KLF4 (Kruppel-like factor 4) • MSI2 (Musashi RNA Binding Protein 2)
|
KLF4 overexpression
almost2years
KLF14 targets ITGB1 to inhibit the progression of cervical cancer via the PI3K/AKT signalling pathway. (PubMed, Discov Oncol)
KLF14 directly targeted ITGB1 to regulate its downstream PI3K/AKT signalling pathway. In summary, KLF14 inhibits the progression of cervical cancer by targeting ITGB1 via the PI3K/AKT signalling pathway.
Journal
|
ITGB1 (Integrin Subunit Beta 1)
|
KLF4 overexpression
almost2years
In vivo temporal resolution of acute promyelocytic leukemia progression reveals a role of Klf4 in suppressing early leukemic transformation. (PubMed, Genes Dev)
Furthermore, we characterized the dynamic alterations in the Klf4 cis-regulatory network during APL progression and demonstrated that ectopic Klf4 overexpression can suppress self-renewal and reverse the differentiation block induced by PML-RARα. Our study provides a comprehensive in vivo temporal dissection of the epigenomic and topological reprogramming induced by an oncogenic TF and illustrates how topological architecture can be used to identify new drivers of malignant transformation.
Preclinical • Journal
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia) • KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
almost2years
EMT-related transcription factors and protein stabilization mechanisms involvement in cadherin switch of head and neck squamous cell carcinoma. (PubMed, Exp Cell Res)
The presence of HSP-70 ensures the membranous localization of E-cadherin, therefore, the ability of cells to form cadherin/catenin complexes and cellular linkages. In conclusion, KLF4 is a major regulator of the epithelial cadherin-adhesion in HNSCC.
Journal
|
IL6 (Interleukin 6) • CDH1 (Cadherin 1) • KLF4 (Kruppel-like factor 4) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
KLF4 overexpression • CDH1 expression
almost2years
The role of KLF4 in melanogenesis and homeostasis in sheep melanocytes. (PubMed, Acta Histochem)
In addition, KLF4 overexpression significantly increased melanin production and pigment-related gene expression. Collectively, our findings show that KLF4 is important for coat color formation and melanocyte homeostasis.
Journal
|
KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
almost2years
Silencing of lncRNA CHRM3-AS2 Expression Exerts Anti-Tumour Effects Against Glioma via Targeting microRNA-370-5p/KLF4. (PubMed, Front Oncol)
Overexpression of KLF4 also weakened the anti-tumour effect of CHRM3-AS2 silencing in mice. Silencing of CHRM3-AS2 expression inhibited the malignant progression of glioma by regulating miR-370-5p/KLF4 expression.
Journal
|
KLF4 (Kruppel-like factor 4) • CHRM3 (Cholinergic Receptor Muscarinic 3) • MIR370 (MicroRNA 370)
|
KLF4 overexpression
almost2years
KLF14 alleviated breast cancer invasion and M2 macrophages polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling. (PubMed, Cell Signal)
Collectively, KLF14 suppressed breast cancer cell invasion and M2 macrophage polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling, and these findings would provide a new potential target against breast cancer.
Journal
|
RHOA (Ras homolog family member A) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
KLF4 overexpression
2years
The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4. (PubMed, Thorac Cancer)
Our study revealed that OTUD1 suppresses NSCLC progression by mediating KLF4 stabilization, which suggests a potential gene target for the future treatment of NSCLC.
Journal
|
KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
2years
MiR-135b-5p is an oncogene in pancreatic cancer to regulate GPRC5A expression by targeting transcription factor KLF4. (PubMed, Cell Death Discov)
Besides, cell malignant phenotypes could be inhibited through reducing miR-135b-5p level, but they were restored by GPRC5A. Our results stressed that KLF4, as a vital target of miR-135b-5p, could influence promoter region of GPRC5A, thus affecting the malignant progression of pancreatic cancer.
Journal
|
KLF4 (Kruppel-like factor 4) • MIR135B (MicroRNA 135b) • GPRC5A (G Protein-Coupled Receptor Class C Group 5 Member A)
|
KLF4 overexpression
over2years
LINC00852 is associated with poor prognosis in non-small cell lung cancer patients and its inhibition suppresses cancer cell proliferation and chemoresistance via the hsa-miR-145-5p/KLF4 axis. (PubMed, J Gene Med)
LINC00852 may be a prognostic biomarker for NSCLC. The epigenetic signaling pathway of LINC00852/hsa-miR-145-5p/KLF4 may be considered as a novel molecular target to fight NSCLC.
Clinical • Journal
|
KLF4 (Kruppel-like factor 4)
|
KLF4 overexpression
|
cisplatin
almost3years
3,3'-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer. (PubMed, Front Oncol)
The level of KLF4 is correlated with the sensitivity of MCF-7 and T47D cells to PTX. DIM could enhance the antitumor efficacy of PTX on MCF-7 and T47D cells by regulating DNMT1 and KLF4.
Journal
|
KLF4 (Kruppel-like factor 4) • DNMT1 (DNA methyltransferase 1)
|
KLF4 overexpression • DNMT1 overexpression
|
paclitaxel